AKT1 and prostate carcinoma: In prostate cancer, the combination of quercetin and arctigenin inhibits prostate cancer cell proliferation by inhibiting the expression of the androgen receptor (AR) and phosphoinositide 3-kinase (PI3K)/Akt pathways and several oncogenic small RNAs (including microRNA-21, microRNA-19b, and microRNA-148a) [74].